Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00942188 | A Study of LY2189102 in Patients With Type 2 Diabetes | PHASE2 | COMPLETED | 106 | — | — | Jun 1, 2009 | Nov 1, 2010 | Sep 18, 2019 | 18 | United States |
Change in HbA1c from baseline following 12 weeks of therapy (that is, HbA1c at week 12 minus HbA1c at baseline). The Least Squares (LS) Mean Value was based on an analysis of covariance (ANCOVA) model with treatment and site as class variables and baseline HbA1c as a continuous covariate.
| Arm | Type | Description |
|---|---|---|
| 0.6 milligrams (mg) LY2189102 | EXPERIMENTAL | - |
| 18 mg LY2189102 | EXPERIMENTAL | - |
| 180 mg LY2189102 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | 0.9% Sodium Chloride |
| Name | Type | Description |
|---|---|---|
| LY2189102 | DRUG | Participants received 2 subcutaneous (SC) injections weekly for 12 weeks. |
| Placebo | DRUG | Participants received 2 SC injections weekly for 12 weeks. |
Inclusion Criteria: * Have Type 2 Diabetes and confirmed by fasting C-peptide levels greater than or equal to 0.8 nanograms per milliliter \[ng/ml\]), with duration of more than 3 months. * Body mass index between 25 and 40 kilograms per square meter (kg/m2). * Stable on diet and exercise alone, wi...